Trulieve Investors Get a Two-Pronged Update: Delaware Move Approved, DEA Clock Keeps Ticking
Published on 08/18/2026 at 06:31 | Redaktion boerse-global.de
Shareholders of the Florida-based cannabis operator have handed management a resounding vote of confidence, with 99.5 percent backing the company's reincorporation in Delaware. The corporate relocation lands at a moment when the regulatory picture in Washington is shifting beneath the industry's feet—though the pace of change remains frustratingly slow for those hoping for a quick resolution.
The Delaware move is designed to modernize the legal architecture of the multi-state operator as it positions itself for the next phase of the US market. It is a structural adjustment rather than a headline-grabbing transaction, but the near-unanimous support signals that investors are comfortable with the direction set by the executive team.
DEA Hearing Process Reaches a Key Milestone
On the federal front, a procedural deadline has come and gone without fanfare. Monday, August 17, 2026, marked the cutoff for parties to file written closing arguments in the Drug Enforcement Administration's expedited hearing on comprehensive cannabis rescheduling. Administrative Law Judge Derek Julius had granted the extension of the record, allowing submissions of up to 50 pages that could address both final arguments and questions raised by the court during oral proceedings.
The hearing itself opened on June 29, 2026, with the DEA inviting seven parties opposed to the rescheduling effort to participate. Transcripts were circulated to all involved within 48 hours of each session, and corrections were accepted until the August 17 deadline, after which the official record will be finalized.
Should investors sell immediately? Or is it worth buying Trulieve?
What happens next is less certain. Judge Julius will now draft a recommendation on whether the government should proceed with moving cannabis from Schedule I to Schedule III. There is no timeline attached to this phase. Once his recommendation lands, parties can file objections before the entire package moves to the DEA administrator, whose final decision would then be subject to judicial review.
The Financial Stakes for Trulieve
The outcome matters enormously for the company's balance sheet. A successful comprehensive rescheduling would eliminate the tax burden imposed by Section 280E of the Internal Revenue Code—a provision that prevents cannabis businesses from deducting ordinary expenses. More significantly, it could unlock retroactive tax relief covering the bulk of Trulieve's uncertain tax position, which currently stands at $598 million.
Management has been vocal in its support of the reform effort. During the most recent earnings call, executives pointed to Attorney General Blanche's decision to revive the comprehensive rescheduling process, noting that the hearings had wrapped up the previous month. The company continues to expect a final determination before the end of 2026.
Legal observers, however, caution against reading too much into a missed filing deadline. The submission of closing arguments is not the same as a finished rule. The judge's recommendation, potential objections, and the administrator's final call all remain pending, with no fixed dates attached. The practical takeaway for investors is not that a decision is imminent, but rather that the process is advancing—and preparation for either outcome is prudent.
A Narrower Reform Already in Place
The current hearing builds on a more limited reform that took effect earlier this year. In April, acting Attorney General Todd Blanche signed an order moving FDA-approved cannabis-based medications and state-licensed medical cannabis from Schedule I to Schedule III. That directive itself followed a December mandate and represents a clear break from the previous classification.
Yet that earlier order is already facing legal challenges. Lawsuits filed by Smart Approaches to Marijuana and several state attorneys general have been consolidated before a federal appeals court.
Even a favorable outcome in the current proceeding would have limits. A Schedule III classification would not legalize state cannabis markets, nor would it automatically bring licensed operators into compliance with federal law. The FDA's oversight of drug products would remain unchanged. Companies banking on Schedule III as a comprehensive solution to their federal exposure are relying on precisely the assumption that the court questioned during the hearing.
Political Positioning and Industry Headwinds
Beyond the regulatory machinery, Trulieve's leadership has been active on the political front. Media reports indicate that CEO Kim Rivers contributed $750,000 to Donald Trump's inauguration fund. The broader industry has channeled roughly $11.5 million into political action committees ahead of the 2026 midterm elections.
Trulieve at a turning point? This analysis reveals what investors need to know now.
These efforts unfold against a shifting public opinion landscape. Gallup polling shows support for legalization slipping from 70 percent in 2023 to 64 percent currently, with the decline particularly pronounced among Republicans, where backing fell from 53 percent to 40 percent.
The company has also had to bat down claims from an unexpected quarter. Lev Parnas, the former associate of Rudy Giuliani who served time in federal prison for his role in the Ukraine affair, has alleged that he was offered a ten percent stake in Trulieve back in 2018. Parnas, now running for Congress on a full-legalization platform, saw his account firmly rejected by the company.
Consolidation Continues Elsewhere
While Trulieve focuses on internal structural consolidation, competitors are pursuing growth through acquisition. Curaleaf has been expanding via deals totaling $272 million. Trulieve, for now, appears content to strengthen its own foundation and position itself to capitalize on the tax advantages that a Schedule III classification could deliver.
The overwhelming shareholder approval of the Delaware move underscores confidence in the current strategy. The next concrete signal on the federal reform timeline will be the administrative judge's recommendation, which will arrive once the review of closing arguments is complete. No date has been set.
Ad
Trulieve Stock: New Analysis - 18 August
Fresh Trulieve information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
